Transcriptional activation of cyclin-dependent kinase inhibitor, p21waf1 gene by treatment with a differentiation inducing agent, Vesnarinone in a human salivary gland cancer cell line

Journal of Experimental and Clinical Cancer Research

Volumn 22, Issue 1, 2003, Pages 57-60

  Omotehara, F ^a   Nakashiro, K ^b   Uchida, D ^b   Hino, S ^b   Fujimori, T ^a   Kawamata, Hitoshi ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Differentiation inducing agent; P21waf1; Salivary gland cancer

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; MESSENGER RNA; PIPERANOMETOZINE; PROTEIN P21;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; GENE ACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN INDUCTION; SALIVARY GLAND CANCER; SQUAMOUS CELL CARCINOMA; TRANSCRIPTION INITIATION;

ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL DIVISION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PLASMIDS; QUINOLINES; RNA, MESSENGER; SALIVARY GLAND NEOPLASMS; TRANS-ACTIVATION (GENETICS); TUMOR CELLS, CULTURED;

EID: 12244304143     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Harrison L.B., Sessions R.B., Hong W.K.: Head and neck cancer: a multidisciplinary approach. Philadelphia: Lippincott-Raven Publishers, 1999.
2. Takahashi Y., Mai M.: Significance of prolonged NC as an endpoint of chemotherapy for solid tumors. Gan To Kagaku Ryoho. 27: 683-688, 2000.
3. Kawamata H., Azuma M., Yanagawa T., et al.: Effect of dibutyryl cyclic adenosine 3′, 5′-monophosphate on morphological features and biological markers of human salivary myoepithelial cell line in culture. Cancer Invest. 10: 111-127, 1992.
4. Sato M., Harada k., Yoshida H.: Induction of differentiation and apoptosis, and LeY antigen expression by treatment with 3, 4-dihydro-6-[4-(3, 4-dimethoxybenzoyl)-1-piperazinyl]-2-(1H)-quinolinone (vesnarinone) in a human salivary cancer cell line. Acta Histochem. Cytochem. 27: 591-599, 1994.
5. Sato M., Harada k., Yoshida H.: Characteristics of anti-tumor activity of 3, 4-dihydro-6-[4-(3, 4-dimethoxybenzoyl)-1-piperazinyl]-2-(1H)-quinolinone (vesnarinone) against a human adenoid squamous carcinoma-forming cell line grown in a athymic nude mice. Cancer Lett. 91: 1-9, 1995.
6. Sato M., Harada K., Yura Y., et al.: Induction of tumour differentiation and apoptosis and LeY antigen expression in treatment with differentiation-inducing agent, vesnarinone, of a patient with salivary adenoid cystic carcinoma. Apoptosis 2: 106-113, 1997.
7. waf1, by treatment with 3, 4-dihydro-6-[4-(3, 4-dimethoxybenzoyl)-1-piperazinyl]-2-(1H)-quinolinone (vesnarinone) in a human salivary cancer cell line with mutant p53 gene. Cancer Lett. 112: 181-189, 1997.
8. Yanagawa T., Hayashi Y., Yoshida H., et al.: An adenoid squamous carcinoma-forming cell line established from an oral keratinizing squamous cell carcinoma expressing carcinoembryonic antigen. Am. J. Pathol. 124: 496-509, 1986.
9. Carmichael J., DeGraff W.G., Gazdar A.F., et al.: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of radiosensitivity. Cancer Res. 15: 943-946, 1987.
10. Nakashiro K., Kawamata H., Hino S., et al.: Down-regulation of TSC-22 (transforming growth factor beta-stimulated clone 22) markedly enhances the growth of a human salivary gland cancer cell line in vitro and in vivo. Cancer Res. 77: 549-555, 1998.
11. Kawamata H., Hattori K., Omotehara F., et al.: Balance betw-een activated-STAT and MAP kinase regulates the growth of human bladder cell lines after treatment with epidermal growth factor. Int. J. Oncol. 15: 661-667, 1999.
12. Struhl K., Moqtaderi Z.: The TAFs in the HAT. Cell 94: 1-4, 1998.